<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965116</url>
  </required_header>
  <id_info>
    <org_study_id>210357</org_study_id>
    <nct_id>NCT04965116</nct_id>
  </id_info>
  <brief_title>Progestin-Only Pill Use and Breastfeeding Study</brief_title>
  <official_title>Progestin-Only Pill Use and Breastfeeding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the impact of early initiation (less than one week postpartum) and&#xD;
      delayed initiation (4 weeks postpartum) of two types of progestin-only contraceptive pills&#xD;
      (POPs) on maternal, breastmilk, and infant outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled randomized controlled trial enrolling dyads of mothers and their&#xD;
      newborn babies. We will explore if the type and timing of initiation of pills is acceptable&#xD;
      to the user with minimal side effects, impacts the supply or composition of breastmilk,&#xD;
      and/or affects infant growth.&#xD;
&#xD;
      Women will be randomly assigned to 1 of 3 groups and will be blinded to group assignment:&#xD;
&#xD;
        1. immediate initiation of drospirenone-containing progestin-only pills (d-POPs),&#xD;
&#xD;
        2. immediate initiation of norethindrone-containing progestin-only pills (n-POPs)&#xD;
&#xD;
        3. immediate initiation of a placebo pill for one month followed by d-POPs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 28, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants exclusively breastfeeding at 2 months postpartum</measure>
    <time_frame>8 weeks postpartum</time_frame>
    <description>Exclusive breastfeeding will be assessed at 8 weeks postpartum through an email self-reported survey. Type of infant feeding will be collected weekly beginning with enrollment to ascertain the length of time exclusively breastfeeding and date of stopping if applicable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding supplementation type</measure>
    <time_frame>Weeks 2-8 postpartum</time_frame>
    <description>If not exclusively breastfeeding, type of supplementation will be collected via text and email surveys.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants using progestin-only pills at 2 months postpartum</measure>
    <time_frame>8 weeks postpartum</time_frame>
    <description>Type of contraception being used at 8 weeks postpartum will be assessed through an email self-reported survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal bleeding</measure>
    <time_frame>4 and 8 weeks postpartum</time_frame>
    <description>Number of days of any bleeding and spotting in last month will be collected via self-reported email survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with contraception method</measure>
    <time_frame>4 and 8 weeks postpartum</time_frame>
    <description>Overall satisfaction and if participants would recommend the current method of contraception they are using to a friend will be ascertained from an email self-report survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein content of breastmilk</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Mid-feeding breastmilk samples will be collected and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate content of breastmilk</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Mid-feeding breastmilk samples will be collected and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat content of breastmilk</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Mid-feeding breastmilk samples will be collected and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal perception of milk supply</measure>
    <time_frame>4 and 8 weeks postpartum</time_frame>
    <description>Self-reported perception of adequacy of breastmilk supply will be collected with the 20-item Hill and Humenick Lactation Scale. Minimum scale score is 20 and maximum is 140, with higher scores representing a more positive perception of breastfeeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infant weight</measure>
    <time_frame>Baseline and 4 weeks after delivery</time_frame>
    <description>Weight in grams will be compared over 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infant height</measure>
    <time_frame>Baseline and 4 weeks after delivery</time_frame>
    <description>Length as measured on a marked board to the nearest millimeter will be compared over 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infant head circumference</measure>
    <time_frame>Baseline and 4 weeks after delivery</time_frame>
    <description>The maximum diameter through the glabella and occiput is found and measured with a tape measure and recorded to the nearest millimeter and compared over 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Contraception</condition>
  <condition>Breastfeeding</condition>
  <arm_group>
    <arm_group_label>Early Initiation d-POPs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation of d-POPs 120-160 hours after delivery. Dosing is 4mg daily for 24 days followed by 4 daily inactive tablets for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Initiation n-POPs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation of n-POPs 120-160 hours after delivery. Dosing is 0.35mg daily for 28 days for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interval Initiation of d-POPs</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo starting 120-160 hours after delivery, continuing for 28 days. Followed by 24 days of 4mg daily of d-POPs and 4 daily inactive tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progestin Only Contraceptive Pills</intervention_name>
    <description>Daily pill (placebo or active tablet)</description>
    <arm_group_label>Early Initiation d-POPs</arm_group_label>
    <arm_group_label>Early Initiation n-POPs</arm_group_label>
    <arm_group_label>Interval Initiation of d-POPs</arm_group_label>
    <other_name>Slynd</other_name>
    <other_name>Camila</other_name>
    <other_name>Micronor</other_name>
    <other_name>Errin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  13 years of age and older&#xD;
&#xD;
          -  Desires to use POPs for 3 months&#xD;
&#xD;
          -  Speak English or Spanish&#xD;
&#xD;
          -  Had a vaginal or cesarean delivery of a singleton full term (â‰¥37 weeks) infant less&#xD;
             than 168 hours prior&#xD;
&#xD;
          -  Intends to breastfeed exclusively for 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Desire another pregnancy in less than 6 months&#xD;
&#xD;
          -  Do not intend to exclusively breastfeed&#xD;
&#xD;
          -  Do not have access to a telephone&#xD;
&#xD;
          -  Have any medical contraindication to POPs&#xD;
&#xD;
          -  Have any contraindication to breastfeeding, including maternal illegal drug use,&#xD;
             history of augmentation or reduction, infant with major congenital anomaly&#xD;
&#xD;
          -  Cognitively impaired&#xD;
&#xD;
          -  Currently incarcerated&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Averbach, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gennifer Kully, MSc</last_name>
    <phone>858-329-4464</phone>
    <email>familyplanningresearch@health.ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gennifer Kully, MSc</last_name>
      <phone>858-329-4464</phone>
      <email>familyplanningresearch@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Averbach, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sarah Averbach, MD MAS</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Minipill</keyword>
  <keyword>Progestin-only Pill</keyword>
  <keyword>Postpartum</keyword>
  <keyword>Slynd</keyword>
  <keyword>Camila</keyword>
  <keyword>Micronor</keyword>
  <keyword>Infant growth</keyword>
  <keyword>Breastmilk</keyword>
  <keyword>Drospirenone</keyword>
  <keyword>Norethindrone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

